PBYIPuma Biotechnology, Inc.

$305M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M

Gross Profit

$5M74.9% margin

Operating Income

-$77M-1274.3% margin

Net Income

-$77M-1270.0% margin

EPS (Diluted)

$-2.07

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$182M

Total Liabilities

$103M

Stockholders' Equity

$79M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$0	—
Gross Profit	$5M	$0	—
Operating Income	-$77M	-$66M	-17.3%
Net Income	-$77M	-$66M	-17.3%

PBYI Q3 2017 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena